Stifel analyst Laura Prendergast raised the firm’s price target on Nuvalent (NUVL) to $135 from $115 and keeps a Buy rating on the shares after the company presented topline pivotal data from the registration enabling Ph1/2 ALKove-1 study of neladalkib in tyrosine kinase inhibitor pre-treated patients with advanced ALK-positive non-small cell lung cancer. The firm considers these data and EAP enrollment commentary “highly encouraging,” the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVL:
- Nuvalent price target raised to $149 from $140 at Leerink
- Nuvalent’s Neladalkib: Promising ALK+ NSCLC Treatment with Strong Phase 2 Data and De-risked Approval Path
- Nuvalent’s Promising Future: Buy Rating Backed by ALKOVE-1 Study Success and Strategic Growth Plans
- Nuvalent price target raised to $155 from $130 at H.C. Wainwright
- Nuvalent Announces Positive Data for ALKOVE-1 Trial